{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T14:34:58Z","timestamp":1790260498525,"version":"4.1.0"},"reference-count":10,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T00:00:00Z","timestamp":1775433600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T00:00:00Z","timestamp":1775433600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["movementdisorders.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Movement Disord Clin Pract"],"published-print":{"date-parts":[[2026,9]]},"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n Peripheral neuropathy has been described in Parkinson's disease (PD) patients receiving continuous levodopa delivery. Whether subcutaneous foslevodopa\/foscarbidopa (fLD\/fCD) infusion carries a similar risk remains unclear.<\/jats:p>\n <\/jats:sec>\n \n Cases<\/jats:title>\n We report four PD patients treated with continuous subcutaneous fLD\/fCD who experienced clinical and electrophysiological worsening of peripheral neuropathy after treatment initiation. At baseline, none reported functional neuropathic symptoms, although electrophysiological evidence of mild subclinical peripheral neuropathy and\/or biochemical abnormalities was present. Neuropathic symptoms developed within a few months of fLD\/fCD initiation and were associated with vitamin B6 and\/or B12 deficiency and persistent hyperhomocysteinemia. In all cases, electrophysiological deterioration accompanied symptoms emergence.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Although causality cannot be established, these cases suggest that fLD\/fCD infusion may be associated with aggravation of pre\u2010existing peripheral neuropathy, despite non\u2010enteral administration, supporting a potential systemic metabolic contribution. These findings underscore the importance of baseline assessment and longitudinal monitoring of peripheral nerve function and B\u2010vitamin status in patients receiving fLD\/fCD. Optimal vitamin supplementation strategies in this setting remain to be defined.<\/jats:p>\n <\/jats:sec>","DOI":"10.1002\/mdc3.70629","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T02:05:13Z","timestamp":1775527513000},"page":"2236-2241","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Peripheral Neuropathy during Subcutaneous Foslevodopa\/Foscarbidopa Infusion in Parkinson's Disease: A Case Series"],"prefix":"10.1002","volume":"13","author":[{"given":"Lucie","family":"Vial\u2010Daragon","sequence":"first","affiliation":[{"name":"Parkinson Expert Center, Neurology Department Clermont\u2010Ferrand University Hospital, IGCNC, Universit\u00e9 Clermont Auvergne, NS\u2010Park\/FCRIN Network Clermont\u2010Ferrand France"},{"name":"Electromyography Unit, Neurology Department Clermont\u2010Ferrand University Hospital Clermont\u2010Ferrand France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Poncet\u2010Megemont","sequence":"additional","affiliation":[{"name":"Electromyography Unit, Neurology Department Clermont\u2010Ferrand University Hospital Clermont\u2010Ferrand France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Derost","sequence":"additional","affiliation":[{"name":"Parkinson Expert Center, Neurology Department Clermont\u2010Ferrand University Hospital, IGCNC, Universit\u00e9 Clermont Auvergne, NS\u2010Park\/FCRIN Network Clermont\u2010Ferrand France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6994-2985","authenticated-orcid":false,"given":"Charlotte","family":"Beal","sequence":"additional","affiliation":[{"name":"Parkinson Expert Center, Neurology Department Clermont\u2010Ferrand University Hospital, IGCNC, Universit\u00e9 Clermont Auvergne, NS\u2010Park\/FCRIN Network Clermont\u2010Ferrand France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berengere","family":"Debilly","sequence":"additional","affiliation":[{"name":"Parkinson Expert Center, Neurology Department Clermont\u2010Ferrand University Hospital, IGCNC, Universit\u00e9 Clermont Auvergne, NS\u2010Park\/FCRIN Network Clermont\u2010Ferrand France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Marques","sequence":"additional","affiliation":[{"name":"Parkinson Expert Center, Neurology Department Clermont\u2010Ferrand University Hospital, IGCNC, Universit\u00e9 Clermont Auvergne, NS\u2010Park\/FCRIN Network Clermont\u2010Ferrand France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,4,6]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26073"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.prdoa.2024.100239"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1017\/cjn.2021.72"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.24308"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27356"},{"key":"e_1_2_8_7_1","first-page":"73","article-title":"Peripheral neuropathy associated with levodopa\u2013carbidopa intestinal gel","volume":"28","author":"Merola A","year":"2016","journal-title":"Parkinsonism Relat Disord"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25585"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.30297"},{"issue":"3","key":"e_1_2_8_10_1","first-page":"221","article-title":"Role of homocysteine in the treatment of Parkinson's disease","volume":"20","author":"M\u00fcller T","year":"2020","journal-title":"Expert Rev Neurother"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11011-014-9520-1"}],"container-title":["Movement Disorders Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mdc3.70629","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/mdc3.70629","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mdc3.70629","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T09:18:15Z","timestamp":1790068695000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mdc3.70629"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,6]]},"references-count":10,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1002\/mdc3.70629"],"URL":"https:\/\/doi.org\/10.1002\/mdc3.70629","archive":["Portico"],"relation":{},"ISSN":["2330-1619","2330-1619"],"issn-type":[{"value":"2330-1619","type":"print"},{"value":"2330-1619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,6]]},"assertion":[{"value":"2026-01-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}